<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Mullen PJ</dc:creator>
  <dc:creator>Lüscher B</dc:creator>
  <dc:creator>Scharnagl H</dc:creator>
  <dc:creator>Krähenbühl S</dc:creator>
  <dc:creator>Brecht K</dc:creator>
  <dc:date>2010</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The mechanism of statin-induced skeletal muscle myopathy is poorly understood. We investigated how simvastatin affects cholesterol metabolism, ubiquinone levels, and the prenylation and N-linked glycosylation of proteins in C2C12 myotubes. We used liver HepG2 cells for comparison, as their responses to statins are well-characterized in terms of their cholesterol metabolism (in contrast to muscle cells), and statins are well-tolerated in the liver. Differences between the two cell lines could indicate the mechanism behind statin-induced myopathy. Simvastatin reduced de novo cholesterol production in C2C12 myotubes by 95% after 18h treatment. The reduction was 82% in the HepG2 cells. Total cholesterol pools, however, remained constant in both cell lines. Simvastatin treatment similarly did not affect total ubiquinone levels in the myotubes, unlike in HepG2 cells (22% reduction in CoQ10). Statin treatment reduced levels of Ras and Rap1 prenylation in both cell lines, whereas N-linked glycosylation was only affected in C2C12 myotubes (21% reduction in rate). From these observations, we conclude that total cholesterol and ubiquinone levels are unlikely to be involved in statin-mediated myopathy, but reductions in protein prenylation and especially N-linked glycosylation may play a role. This first comparison of the responses to simvastatin between liver and skeletal muscle cell lines may be important for future research directions concerning statin-induced myopathy.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/143312</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bcp.2009.12.007</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20018177</dc:relation>
  <dc:source>Biochemical pharmacology. - 2010</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Cells, Cultured</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Cholesterol</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Glycosylation</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Hep G2 Cells</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Hydroxymethylglutaryl-CoA Reductase Inhibitors</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Muscle Fibers, Skeletal</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Muscular Diseases</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Protein Prenylation</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">RNA, Messenger</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Receptors, LDL</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Simvastatin</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Sterol Regulatory Element Binding Protein 2</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Ubiquinone</dc:subject>
  <dc:title xmlns:ns15="xml" ns15:lang="en">Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
